Valuation: Silence Therapeutics plc

Market Cap 462M 611M 545M 507M 870M 58.8B 876M 6.13B 2.39B 30.01B 2.29B 2.24B 96.46B P/E 2026 *
-19.1x
P/E 2027 * -15.3x
Enterprise Value 329M 435M 388M 361M 619M 41.85B 624M 4.36B 1.7B 21.36B 1.63B 1.6B 68.66B EV / Sales 2026 *
1,019x
EV / Sales 2027 * 383x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -
3 months+166.67%
6 months+100.00%
Current year+100.00%
1 month 4
Extreme 4
4
Current year 1.06
Extreme 1.06
5.99
1 year 1.06
Extreme 1.06
5.99
3 years 0.5
Extreme 0.4986
14.75
5 years 0.5
Extreme 0.4986
46.5
10 years 0.5
Extreme 0.4986
46.5
Manager TitleAgeSince
Chief Executive Officer 72 30/11/2025
Director of Finance/CFO 54 31/01/2022
Chief Tech/Sci/R&D Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 63 20/06/2018
Chairman 72 31/12/2003
Director/Board Member 65 04/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 611M
+4.16%+3.42%+49.37%+94.17% 74.31B
-0.37%-3.81%+19.75%+78.12% 56.95B
+1.63%-1.61%+3.83%+36.89% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.60%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.47%-0.15%+54.58%+128.67% 43.73B
Weighted average by Cap. +1.77%-0.46%+58.43%+137.17%

Financials

2026 *2027 *
Net sales 322K 426K 380K 354K 607K 41.06M 612K 4.28M 1.67M 20.95M 1.6M 1.57M 67.36M 751K 992K 885K 825K 1.41M 95.57M 1.42M 9.97M 3.88M 48.78M 3.73M 3.64M 157M
Net income -42.14M -55.71M -49.7M -46.3M -79.35M -5.37B -79.94M -559M -218M -2.74B -209M -205M -8.8B -71.01M -93.89M -83.76M -78.03M -134M -9.04B -135M -943M -367M -4.61B -352M -345M -14.83B
Net Debt -133M -176M -157M -146M -251M -16.95B -252M -1.77B -688M -8.65B -661M -646M -27.8B -174M -230M -205M -191M -328M -22.16B -330M -2.31B -899M -11.31B -864M -845M -36.36B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.14USD
Average target price
33.00USD
Spread / Average Target
+225.44%

Quarterly revenue - Rate of surprise